Promis Neurosciences (PMN) to Release Earnings on Thursday

Posted by on Aug 12th, 2026

Promis Neurosciences (NASDAQ:PMN – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Promis Neurosciences to announce earnings of ($1.3786) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20). On average, analysts expect Promis Neurosciences to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Promis Neurosciences Price Performance

Promis Neurosciences stock opened at $14.97 on Wednesday. The company has a market capitalization of $134.28 million, a price-to-earnings ratio of -1.03 and a beta of -0.23. Promis Neurosciences has a one year low of $6.27 and a one year high of $27.40. The company’s fifty day moving average price is $12.44 and its two-hundred day moving average price is $13.52.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Brookline Capital Markets upgraded Promis Neurosciences to a “strong-buy” rating in a research note on Wednesday, May 20th. Weiss Ratings downgraded Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Zacks Research raised Promis Neurosciences to a “hold” rating in a research note on Tuesday, June 9th. HC Wainwright restated a “buy” rating on shares of Promis Neurosciences in a report on Wednesday, July 15th. Finally, Cantor Fitzgerald started coverage on Promis Neurosciences in a research report on Tuesday, June 30th. They set an “overweight” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.50.

Get Our Latest Stock Report on Promis Neurosciences

Institutional Investors Weigh In On Promis Neurosciences

A hedge fund recently raised its stake in Promis Neurosciences stock. Armistice Capital LLC grew its holdings in Promis Neurosciences (NASDAQ:PMN – Free Report) by 39.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,974,518 shares of the company’s stock after purchasing an additional 836,622 shares during the quarter. Armistice Capital LLC owned about 5.53% of Promis Neurosciences worth $1,264,000 as of its most recent filing with the SEC. 50.13% of the stock is owned by institutional investors and hedge funds.

Promis Neurosciences Company Profile

(Get Free Report)

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.

Featured Stories

Earnings History for Promis Neurosciences (NASDAQ:PMN)

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.